Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Nivolumab in Adults Living With HIV on ART
NCT05187429Phase 2Recruiting
- Sponsor
- University of Melbourne
- Start
- Jan 2023
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nivolumab in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by University of Melbourne. Primary endpoint: Treatment-Emergent Adverse Events at 23 weeks. Started Jan 2023; status: recruiting.
02
Drugs
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05187429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187429.